Spencewind3971

SENTIX (ENGOT-CX2/CEEGOG-CX1) is an international, multicentre, prospective observational trial evaluating sentinel lymph node (SLN) biopsy without pelvic lymph node dissection in patients with early-stage cervical cancer. We report the final preplanned analysis of the secondary end-points SLN mapping and outcomes of intraoperative SLN pathology.

Forty-seven sites (18 countries) with experience of SLN biopsy participated in SENTIX. We preregistered patients with stage IA1/lymphovascular space invasion-positive to IB2 (4cm or smaller or 2cm or smaller for fertility-sparing treatment) cervical cancer without suspicious lymph nodes on imaging before surgery. SLN frozen section assessment and pathological ultrastaging were mandatory. Patients were registered postoperatively if SLN were bilaterally detected in the pelvis, and frozen sections were negative.

ClinicalTrials.gov (NCT02494063).

We analysed data for 395 preregistered patients. Bilateral detection was achieved in 91% (355/395), and it was unaffecost were located below the iliac vessel bifurcation. selleck chemical SLN frozen section assessment is an unreliable tool for intraoperative triage because it only detects about half of N1 cases.

Gemcitabine plus nab-paclitaxel (Gem-Nab) represents a standard first-line treatment for metastatic pancreatic cancer (mPC), but few data are available for elderly patients. We aimed to add evidence about safety and efficacy of Gem-Nab in this population.

We collected data of 156 patients with mPC aged ≥65 years receiving Gem-Nab. Patients were stratified according to age <70 (group 1 65 patients) and ≥70 years (group 2 91 patients).

The median age was 71 years (range 65-87 years). The toxicity profile was similar between group 1 and 2, except for all-grade anaemia (92.1% vs. 78.7%, respectively; p=0.04) and neurotoxicity (61.9% vs. 40.4%, respectively; p=0.02), also as a result of a lower dose intensity of nab-paclitaxel (83.3% vs. 90.5%, respectively; p=0.04) administered to oldest patients. The response rate was 25.6% (group 1 vs. 2 20.0% vs. 29.7%; p=0.12). After a median follow-up of 26.5 months, median overall survival (OS) and progression-free survival (PFS) were similar between the groups (p>0.05). The starting dose of Gem-Nab did not affect PFS and OS (p>0.05).

Gem-Nab is active and effective in older patients with mPC, with the results in line with the general mPC population enrolled in clinical trials. Mild dose modifications for elderly patients might be considered to improve safety without impairing efficacy.

Gem-Nab is active and effective in older patients with mPC, with the results in line with the general mPC population enrolled in clinical trials. Mild dose modifications for elderly patients might be considered to improve safety without impairing efficacy.Cognitive and neurofeedback training (NFT) studies have demonstrated that training-induced alterations of frontal-midline (FM) theta activity (4-8 Hz) transfer to cognitive control processes. Given that FM theta oscillations are assumed to provide top-down control for episodic memory retrieval, especially for source retrieval, that is, accurate recollection of contextual details of prior episodes, the present study investigated whether FM theta NFT transfers to memory control processes. It was assessed (1) whether FM theta NFT improves source retrieval and modulates its underlying EEG characteristics and (2) whether this transfer extends over two posttests. Over seven NFT sessions, the training group who trained individual FM theta activity showed greater FM theta increase than an active control group who trained randomly chosen frequency bands. The training group showed better source retrieval in a posttraining session performed 13 days after NFT and their performance increases from pre- to both posttraining sessions were predicted by NFT theta increases. Thus, training-induced enhancement of memory control processes seems to protect newly formed memories from proactive interference of previously learned information. EEG analyses revealed that during pretest both groups showed source memory specific theta activity at frontal and parietal sites. Surprisingly, training-induced improvements in source retrieval tended to be accompanied by less prestimulus FM theta activity, which was predicted by NFT theta change for the training but not the control group, suggesting a more efficient use of memory control processes after training. The present findings provide unique evidence for the enhancement of memory control processes by FM theta NFT.

Robust and reliable attenuation correction (AC) is a prerequisite for accurate quantification of activity concentration. In combined PET/MRI, AC is challenged by the lack of bone signal in the MRI from which the AC maps has to be derived. Deep learning-based image-to-image translation networks present itself as an optimal solution for MRI-derived AC (MR-AC). High robustness and generalizability of these networks are expected to be achieved through large training cohorts. In this study, we implemented an MR-AC method based on deep learning, and investigated how training cohort size, transfer learning, and MR input affected robustness, and subsequently evaluated the method in a clinical setup, with the overall aim to explore if this method could be implemented in clinical routine for PET/MRI examinations.

A total cohort of 1037 adult subjects from the Siemens Biograph mMR with two different software versions (VB20P and VE11P) was used. The software upgrade included updates to all MRI sequences. The impact otraining cohort to achieve accurate and robust performance. Using transfer learning, only five subjects were needed to fine-tune the method to large changes to the input images. No clinically relevant differences were found compared to CT-AC, indicating that clinical implementation of our deep learning-based MR-AC method will be feasible across MRI system types using transfer learning and a limited number of subjects.Here, we introduce a nanophotonics concept for optically triggered activation of microglia. Specifically, we synthesized a yolk-shell structured mesoporous silica coated core-shell upconverting nanoparticles (UCNP@ysSiO2). The nanoparticles are loaded with microglia activators-bacterial lipopolysaccharide (LPS) together with indocyanine green (ICG), and then capped with β-cyclodextrin (CD) via selective affinity of this compound to photoswitchable azobenzene (Azo). Upon exposure to NIR light, and subsequent trans- to cis photoisomerization of the Azo group induced by the upconversion light, dissociation of β-CD produces the release of LPS. The released LPS activates microglia through a toll-like receptor 4 mediated pathway, while ICG excited by its absorption of the 800 nm upconversion light, produces local heating, thus synergistically activating microglia through heat shock proteins. We propose that the controlled activation of microglia with deep tissue penetrating NIR triggered drug release, may provide a new strategy for in situ treatment of many brain diseases.